2.4.0.8120 - Disclosure - Related Party - Additional Information (Detail)truefalsefalse1false USDfalsefalse$P01_01_2013To06_30_2013http://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$P01_01_2012To06_30_2012http://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$P01_01_2011To12_31_2011http://www.sec.gov/CIK0001133818duration2011-01-01T00:00:002011-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$P05_10_2007To06_30_2013http://www.sec.gov/CIK0001133818duration2007-05-10T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDfalsefalse$PAsOn12_31_2012http://www.sec.gov/CIK0001133818instant2012-12-31T00:00:000001-01-01T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false USDtruefalse$P01_01_2013To06_30_2013_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7false USDtruefalse$P01_01_2012To06_30_2012_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDtruefalse$PAsOn06_30_2013_ClinicalTrialsMemberbpthComponentOfOtherOperatingCostAndExpensesAxis_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalseClinical Trials [Member]bpth_ComponentOfOtherOperatingCostAndExpensesAxisxbrldihttp://xbrl.org/2006/xbrldibpth_ClinicalTrialsMemberbpth_ComponentOfOtherOperatingCostAndExpensesAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false USDtruefalse$P04_01_2013To06_30_2013_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxishttp://www.sec.gov/CIK0001133818duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalseResearch and Development Expenseus-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_IncomeStatementLocationAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10false USDtruefalse$P04_01_2012To06_30_2012_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxishttp://www.sec.gov/CIK0001133818duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalseResearch and Development Expenseus-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_ResearchAndDevelopmentExpenseMemberus-gaap_IncomeStatementLocationAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11false USDtruefalse$PAsOn06_30_2013_MdAndersonCancerCenterMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_TechnologyLicensesMemberusgaapIncomeStatementLocationAxishttp://www.sec.gov/CIK0001133818instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseMD Anderson Cancer Centerus-gaap_RelatedPartyTransactionsByRelatedPartyAxisxbrldihttp://xbrl.org/2006/xbrldibpth_MdAndersonCancerCenterMemberus-gaap_RelatedPartyTransactionsByRelatedPartyAxisexplicitMemberfalsefalseTechnology Licensesus-gaap_IncomeStatementLocationAxisxbrldihttp://xbrl.org/2006/xbrldibpth_TechnologyLicensesMemberus-gaap_IncomeStatementLocationAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_RelatedPartyTransactionLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse02false 4bpth_AccruedLiabilitiesRelatedPartiesCurrentbpth_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse3705037050USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse3705037050USD$falsetruefalse5truefalsefalse2600026000USD$falsetruefalse6truefalsefalse3705037050USD$falsetruefalse7falsefalsefalse00falsefalsefalse8truefalsefalse2205022050USD$falsetruefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAccrued Liabilities, Related Parties, CurrentNo definition available.false23false 4us-gaap_DueToRelatedPartiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse5000050000falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse5000050000falsefalsefalse5truefalsefalse100000100000falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false24false 4us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9truefalsefalse3206732067falsefalsefalse10truefalsefalse367588367588falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryExpenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 false25false 4us-gaap_AccountsPayableRelatedPartiesCurrentus-gaap_truecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse1001710017falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse1001710017falsefalsefalse5truefalsefalse85828582falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11truefalsefalse1001710017falsefalsefalsexbrli:monetaryItemTypemonetaryAmount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph k -Subparagraph 1 -Article 4 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19 -Subparagraph a -Article 5 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864 false26false 4us-gaap_ResearchAndDevelopmentExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse367588367588falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 false27false 4us-gaap_OtherAssetImpairmentChargesus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1truefalsefalse00falsefalsefalse2truefalsefalse345000345000falsefalsefalse3truefalsefalse345000345000falsefalsefalse4truefalsefalse690000690000falsefalsefalse5falsefalsefalse00falsefalsefalse6truefalsefalse345000345000falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230 false28false 4bpth_PatentExpensebpth_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseverboseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse2258822588USD$falsetruefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryPatent ExpenseNo definition available.false2falseRelated Party - Additional Information (Detail) (USD $)NoRoundingUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.biopathholdings.com/role/RelatedPartyAdditionalInformationDetail118